Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 16, 2021 07:31 ET | Source: PolyPid Ltd.

PolyPid Announces 100th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX₁₀₀ for the Prevention of Post-Abdominal Surgery Incisional Infections

Top-line Data Anticipated by Year End 2021 Enrollment Also Continues to Progress in Company’s Second Phase 3 Clinical Trial, SHIELD II PETAH TIKVA, Israel, Feb. 16, 2021 (GLOBE NEWSWIRE)...
February 10, 2021 07:00 ET | Source: PolyPid Ltd.

PolyPid Ltd. Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results

100 Patients Enrolled into Phase 3 SHIELD I and SHIELD II Trials of D-PLEX100 in Abdominal SurgeryRecently Initiated Phase 3 SHIELD II TrialGranted Breakthrough Therapy Designation from FDA for...
January 27, 2021 07:30 ET | Source: PolyPid Ltd.

PolyPid to Report Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights on February 10, 2021

PETAH TIKVA, Israel, Jan. 27, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and...
December 22, 2020 07:00 ET | Source: PolyPid Ltd.

PolyPid Announces Positive Preclinical Data from OncoPLEX Intra-Tumoral Cancer Therapy Program

Single Local Treatment of OncoPLEX Showed Improved Overall Survival and Significantly Less Tumor Recurrence, and Reduced Systemic Toxicity Compared to Multiple Injections with Standard Systemic...
December 16, 2020 07:00 ET | Source: PolyPid Ltd.

PolyPid Initiates SHIELD II: Second Phase 3 Clinical Trial of D-PLEX₁₀₀ for the Prevention of Post-Abdominal Surgery Incisional Infections

Enrollment in SHIELD I, the First Phase 3 Clinical Trial Continues to Progress, with Top-line Data Anticipated in Second Half of 2021 PETAH TIKVA, Israel, Dec. 16, 2020 (GLOBE NEWSWIRE) -- PolyPid...
December 03, 2020 08:00 ET | Source: PolyPid Ltd.

PolyPid to Host Key Opinion Leader Call Discussing D-PLEX₁₀₀ and the Prevention of Surgical Site Infections

PETAH TIKVA, Israel, Dec. 03, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered, and...
November 24, 2020 08:17 ET | Source: PolyPid Ltd.

PolyPid Granted Breakthrough Therapy Designation from FDA for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Colorectal Surgery

PETAH TIKVA, Israel, Nov. 24, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and...
November 11, 2020 06:30 ET | Source: PolyPid Ltd.

PolyPid Ltd. Provides Corporate Update and Reports Third Quarter 2020 Financial Results

• Over 50% of planned 60 centers for ongoing Phase 3 SHIELD I trial of D-PLEX100 in abdominal surgery have received IRB approval • Phase 3 SHIELD II trial advanced; preparations underway to...
November 04, 2020 08:45 ET | Source: PolyPid Ltd.

PolyPid to Participate in Three Upcoming Investor Conferences

PETAH TIKVA, Israel, Nov. 04, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and...
October 28, 2020 07:00 ET | Source: PolyPid Ltd.

PolyPid to Report Third Quarter 2020 Financial Results and Operational Highlights on November 11, 2020

PETAH TIKVA, Israel, Oct. 28, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and...